Caroline Loewy joined eFFECTOR’s Board of Directors in September 2023. Ms. Loewy is a biopharmaceutical and financial executive with over 25 years of experience in the field. She currently provides strategic advisory services for biopharmaceutical companies. Ms. Loewy is a board member of CymaBay Therapeutics, Inc., Phase BioPharmaceuticals, Inc. and Phoenix Biotech Acquisition Corp. She was a Co-Founder and served as the Chief Business Officer and Chief Financial Officer of Achieve Life Sciences (acquired by OncoGenex Pharmaceuticals, Inc.) from 2015 to 2017. Ms. Loewy has previously held the position of Chief Financial Officer of both public and private biopharmaceutical companies including Tobira Therapeutics (acquired by Allergan Inc.) from 2012 to 2014, Corcept Therapeutics from 2008 to 2011, and Poniard Pharmaceuticals from 2006 to 2008. Prior to her roles in company management, Ms. Loewy spent 11 years as a senior biotechnology equity research analyst at Morgan Stanley and Prudential Securities. Ms. Loewy has leveraged her experience in the medical arena and financial expertise to benefit those affected by rare disease. She is a founding board member of the Global Genes Project and the KCNQ2 Cure Alliance, both non-profit patient advocacy organizations supporting education and research into rare disorders. Ms. Loewy holds a B.A. from the University of California, Berkeley, and a MBA/MS from Carnegie Mellon University.